PCSA vs. XBIO, HILS, FWBI, ENVB, AIMD, LIXT, ASLN, PULM, BFRI, and KA
Should you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Xenetic Biosciences (XBIO), Hillstream BioPharma (HILS), First Wave BioPharma (FWBI), Enveric Biosciences (ENVB), Ainos (AIMD), Lixte Biotechnology (LIXT), ASLAN Pharmaceuticals (ASLN), Pulmatrix (PULM), Biofrontera (BFRI), and Kineta (KA). These companies are all part of the "pharmaceutical preparations" industry.
Xenetic Biosciences (NASDAQ:XBIO) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Processa Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 316.67%. Given Xenetic Biosciences' higher possible upside, analysts clearly believe Processa Pharmaceuticals is more favorable than Xenetic Biosciences.
In the previous week, Processa Pharmaceuticals had 9 more articles in the media than Xenetic Biosciences. MarketBeat recorded 9 mentions for Processa Pharmaceuticals and 0 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.36 beat Processa Pharmaceuticals' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the news media.
15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are held by institutional investors. 9.0% of Xenetic Biosciences shares are held by company insiders. Comparatively, 22.2% of Processa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Xenetic Biosciences received 164 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.24% of users gave Xenetic Biosciences an outperform vote while only 50.00% of users gave Processa Pharmaceuticals an outperform vote.
Xenetic Biosciences has higher revenue and earnings than Processa Pharmaceuticals. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xenetic Biosciences has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Processa Pharmaceuticals has a net margin of 0.00% compared to Processa Pharmaceuticals' net margin of -182.99%. Processa Pharmaceuticals' return on equity of -43.40% beat Xenetic Biosciences' return on equity.
Summary
Xenetic Biosciences and Processa Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Processa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Processa Pharmaceuticals Competitors List
Related Companies and Tools
